Literature DB >> 17264873

Renal histopathology of stone-forming patients with distal renal tubular acidosis.

A P Evan1, J Lingeman, F Coe, Y Shao, N Miller, B Matlaga, C Phillips, A Sommer, E Worcester.   

Abstract

To define the renal tissue changes in stone-forming patients with distal renal tubular acidosis (dRTA), we performed intra-operative papillary and cortical biopsies in five patients. The main abnormalities were plugging of inner medullary collecting ducts (IMCD) and Bellini ducts (BD) with deposits of calcium phosphate in the form of apatite; epithelial cell injury and loss was marked. Plugged ducts were surrounded by interstitial fibrosis, but the fibrosis was generalized, as well, and was a main feature of the histopathology even when plugging was not present. In contrast, common idiopathic calcium oxalate stone formers (SF) never manifest intra-tubule crystals or interstitial fibrosis. Patients with brushite (calcium monohydrogen phosphate) stones and those with cystine stones have many fewer IMCD and BD plugged with apatite (or cystine, in cystinuria), and interstitial fibrosis is limited to the regions around plugged ducts. Patients with dRTA often present a radiographic picture of nephrocalcinosis. Our direct surgical observations reveal that these may be surgically removable stones, especially in patients with well preserved renal function. In all, dRTA SF have a more diffuse papillary renal disease than other SF thus studied, and are also unusual for the degree of interstitial fibrosis.

Entities:  

Mesh:

Year:  2007        PMID: 17264873     DOI: 10.1038/sj.ki.5002113

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  43 in total

1.  Renal stone disease: a commentary on the nature and significance of Randall's plaque.

Authors:  A P Evan; R J Unwin; J C Williams
Journal:  Nephron Physiol       Date:  2011-09-21

Review 2.  The tubular epithelium in the initiation and course of intratubular nephrocalcinosis.

Authors:  Benjamin A Vervaet; Anja Verhulst; Marc E De Broe; Patrick C D'Haese
Journal:  Urol Res       Date:  2010-08-02

3.  Renal histopathology and crystal deposits in patients with small bowel resection and calcium oxalate stone disease.

Authors:  Andrew P Evan; James E Lingeman; Elaine M Worcester; Sharon B Bledsoe; Andre J Sommer; James C Williams; Amy E Krambeck; Carrie L Philips; Fredric L Coe
Journal:  Kidney Int       Date:  2010-04-28       Impact factor: 10.612

4.  Evaluation of low-dose dual energy computed tomography for in vivo assessment of renal/ureteric calculus composition.

Authors:  Harshavardhan Mahalingam; Anupam Lal; Arup K Mandal; Shrawan Kumar Singh; Shalmoli Bhattacharyya; Niranjan Khandelwal
Journal:  Korean J Urol       Date:  2015-08-10

5.  Differentiating calcium oxalate and hydroxyapatite stones in vivo using dual-energy CT and urine supersaturation and pH values.

Authors:  Yu Liu; Mingliang Qu; Rickey E Carter; Shuai Leng; Juan Carlos Ramirez-Giraldo; Giselle Jaramillo; Amy E Krambeck; John C Lieske; Terri J Vrtiska; Cynthia H McCollough
Journal:  Acad Radiol       Date:  2013-12       Impact factor: 3.173

6.  Probiotics for prevention of urinary stones.

Authors:  John C Lieske
Journal:  Ann Transl Med       Date:  2017-01

Review 7.  Nephrolithiasis.

Authors:  Elaine M Worcester; Fredric L Coe
Journal:  Prim Care       Date:  2008-06       Impact factor: 2.907

8.  Medical evaluation and management of urolithiasis.

Authors:  Michelle Jo Semins; Brian R Matlaga
Journal:  Ther Adv Urol       Date:  2010-02

9.  Introduction of a Renal Papillary Grading System for Patients with Nephrolithiasis.

Authors:  Michael Seth Borofsky; Jessica E Paonessa; Andrew P Evan; James C Williams; Fredric L Coe; Elaine M Worcester; James E Lingeman
Journal:  J Endourol B Videourol       Date:  2015-12-03

Review 10.  Physiopathology and etiology of stone formation in the kidney and the urinary tract.

Authors:  Andrew P Evan
Journal:  Pediatr Nephrol       Date:  2009-02-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.